Voyager Therapeutics reported a narrowed net loss of $24.5 million for the second quarter of 2026, primarily driven by a 30% reduction in research and development expenses. The company maintained a solid liquidity position with $148.8 million in cash and marketable securities, providing a projected operational runway into 2028.
Key Highlights
- Lead Alzheimer’s program VY7523 remains on track for tau PET imaging efficacy data in the fourth quarter of 2026.
- Operating expenses decreased significantly to $29.6 million from $41.8 million in the prior year, reflecting successful program prioritization and 2025 restructuring actions.
- Clinical entry for the VY1706 tau silencing gene therapy is expected in the fourth quarter of 2026 following FDA IND clearance.